Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in chemotherapy-naïve advanced NSCLC
NCT02477826Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2015
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02477826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477826.